Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2017

Keesecker S, Saab J, Magro CM, Dokania V, Sclafani AP. Cutaneous Lymphadenoma: A Trichoblastoma with Regressive Inflammatory Changes. Facial Plast Surg. 2017;33(1):109-111.

Postnikoff SD, Johnson JE, Tyler JK. The integrated stress response in budding yeast lifespan extension. Microb Cell. 2017;4(11):368-375.

Magro CM, Olson LC, Fulmer CG. CD30+ T cell enriched primary cutaneous CD4+ small/medium sized pleomorphic T cell lymphoma: A distinct variant of indolent CD4+ T cell lymphoproliferative disease. Ann Diagn Pathol. 2017;30:52-58.

Graff RE, Judson G, Ahearn TU, Fiorentino M, Loda M, Giovannucci EL, et al. Circulating Antioxidant Levels and Risk of Prostate Cancer by TMPRSS2:ERG. Prostate. 2017;77(6):647-653.

Witt AE, Lee C-, Lee TI, Azzam DJ, Wang B, Caslini C, et al. Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer. Oncogene. 2017;36(12):1707-1720.

Natkunam Y, Gratzinger D, de Jong D, Chadburn A, Goodlad JR, Chan JK, et al. Immunodeficiency and Dysregulation: Report of the 2015 Workshop of the Society for Hematopathology/European Association for Haematopathology. Am J Clin Pathol. 2017;147(2):124-128.

Tsang HC, Mathew S, Magro CM. An Aggressive Primary Cutaneous Follicle Center Lymphoma With c-MYC Translocation and CDKN2A (9p21) Deletion: A Case Report and Review of the Literature. Am J Dermatopathol. 2017;39(3):e44-e49.

Simon MS, Westblade LF, Dziedziech A, Visone JE, Furman RR, Jenkins SG, et al. Clinical and Molecular Evidence of Atovaquone and Azithromycin Resistance in Relapsed Babesia microti Infection Associated With Rituximab and Chronic Lymphocytic Leukemia. Clin Infect Dis. 2017;65(7):1222-1225.

Linares JF, Cordes T, Duran A, Reina-Campos M, Valencia T, Ahn CS, et al. ATF4-Induced Metabolic Reprograming Is a Synthetic Vulnerability of the p62-Deficient Tumor Stroma. Cell Metab. 2017;26(6):817-829.e6.

Cheng E, Ko D, Nguyen M, Moo T-, Andreopoulou E, Hoda SA, et al. Residual Pure Intralymphatic Breast Carcinoma Following Neoadjuvant Chemotherapy Is Indicative of Poor Clinical Outcome, Even in Node-Negative Patients. Am J Surg Pathol. 2017;41(9):1275-1282.